The Effects of tDCS on Auditory Hallucination, Insight, Neurocognitive Function and HRV in Patients With Schizophrenia
Schizophrenia, Schizoaffective Disorder, Auditory Hallucination, Verbal
About this trial
This is an interventional treatment trial for Schizophrenia
Eligibility Criteria
Inclusion Criteria:
- Patients who met DSM-IV-TR criteria for schizophrenia or schizoaffective disorder were included in the study. All these patients showed refractory auditory verbal hallucinations,which are defined as the persistence of daily auditory verbal hallucinations without remission in spite of antipsychotic medications at an adequate dosage for at least 3 months.
Exclusion Criteria:
- Pregnancy or breastfeeding.
- Having epilepsy, severe physical illness, any current psychiatric comorbidity or history of substance dependence.
- Having contraindications for transcranial electrical/magnetic stimulation.
- Having intracranial metal foreign bodies.
- Having a history of intracranial neoplasms or surgery, or a history of severe head injuries or cerebrovascular diseases.
Sites / Locations
- Tri-service general hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Sham Comparator
Active tDCS
Sham tDCS
Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 square centimeter). The anode was placed with the middle of the electrode over a point midway between F3 and FP1 (left dorsolateral prefrontal cortex and left prefrontal cortex). The cathode was located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients in the active tDCS group were maintained on their antipsychotic medications throughout the study period.
In sham stimulation, the current was turned on for 30 sec and then ramped down to 0 mA. All patients in the sham tDCS group were maintained on their antipsychotic medications throughout the study period.